CRVS

Down 15.8% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a Turnaround

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Corvus Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Corvus Pharmaceuticals Completes Sale of $10 Million Through Its ATM Program

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results